Drug Trial Radar · NCT04988295
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
776
Actual
Start
Nov 17, 2021
Primary completion
Jul 10, 2023
Study completion Jul 3, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
LazertinibDrug
Lazertinib will be administered orally.
AmivantamabDrug
Amivantamab will be administered as an IV infusion.
PemetrexedDrug
Pemetrexed will be administered as an IV infusion.
CarboplatinDrug
Carboplatin will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)
- Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: up to 4 years 10 months
- Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central ReviewTime frame: Up to 4 years 10 months
Locations
249 sites in 29 countries. Site status is shown where the registry gives one.
Southern Cancer Center, PC
Mobile, Alabama
Arizona Oncology Associates
Tucson, Arizona
City of Hope
Duarte, California
Cedars Sinai Medical Center
Los Angeles, California
University of California Irvine
Orange, California
Rocky Mountain Cancer Centers
Colorado Springs, Colorado
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida
University Cancer And Blood Center LLC
Athens, Georgia
University of Mississippi Medical Center
Jackson, Mississippi
Nebraska Cancer Specialists
Grand Island, Nebraska
Astera Cancer Care
East Brunswick, New Jersey
TriHealth Network
Cincinnati, Ohio
Providence Portland Medical Center
Portland, Oregon
Kaiser Permanente Northwest
Portland, Oregon
Alliance Cancer Specialists
Horsham, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Baptist Cancer Center
Memphis, Tennessee
Texas Oncology-Medical City Dallas
Dallas, Texas
Texas Oncology Baylor Charles A Sammons Cancer Center
Dallas, Texas
Texas Oncology
Grapevine, Texas
Oncology Consultants Texas
Houston, Texas
Texas Oncology - Northeast
Longview, Texas
University of Vermont Medical Center
Burlington, Vermont
University of Virginia
Charlottesville, Virginia
Virginia Cancer Specialists
Fairfax, Virginia
Blue Ridge Cancer Care
Wytheville, Virginia
NorthWest Medical Specialties, PLLC
Puyallup, Washington
Compass Oncology
Vancouver, Washington
CINME Centro de Investigaciones Metabolicas
Caba, Argentina
IADT Instituto Argentino de Diagnostico y Tratamiento
CABA, Argentina
Centro Medico Fleischer
CABA, Argentina
CEMIC (Centro de Educación Médica e Investigaciones Clínicas)
CABA, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
Córdoba, Argentina
Hospital Privado Universitario De Cordoba
Córdoba, Argentina
Hospital Privado de la Comunidad
Mar del Plata, Argentina
Clínica Viedma
Viedma, Argentina
Grand Hopital De Charleroi Site Les Viviers
Charleroi, Belgium
UZA
Edegem, Belgium
UZ Gent
Ghent, Belgium
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium
Showing 40 of 249 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.